by Alison Bass | Mar 8, 2010 | Uncategorized
I have hesitated to weigh in on the debate raging over the proposed changes to the DSM-V (psychiatry’s diagnostic bible), in large part because others more literate in psychiatric minutiae have already done so. To wit: Dr. Allen Frances in the Psychiatric Times,...
by Alison Bass | Feb 25, 2010 | Uncategorized
The glowing review of Judith Warner’s new book, We’ve Got Issues, in The New York Times this week didn’t exactly catch me by surprise — anyone who has read Warner’s guest columns in recent years knows her take on psychiatric drugs —...
by Alison Bass | Feb 18, 2010 | Uncategorized
In my health and science journalism class at Mount Holyoke yesterday, we were talking about all the questions journalists need to ask in deciding whether and how to report on a new medical finding. Two of the key questions that emerged were: 1. did the results come...
by Alison Bass | Feb 8, 2010 | Uncategorized
It’s true that the drug industry was hard hit last year with some pretty hefty fines for the illegal off-label promotion of drugs — $1.4 billion against Eli Lilly for its off-label promotion of Zyprexa and $2.3 billion against Pfizer for doing the same...
by Alison Bass | Jan 29, 2010 | Uncategorized
Those of you in the mood for a serious read might want to check out an article in the Journal of Bioethical Inquiry about the way in which many drug companies use their marketing muscle to mislead physicians and consumers about the safety and effectiveness of their...
